Ibyiciro by'Ubuvuzi

Uburyo bwo kuvura bwagaragaye

Ubuvuzi bwa Virusi ya Oncolytic: Ubuvuzi bwa Kanseri bugezweho

CAR-T yo kurwanya Glioblastoma

Inshinge za Nusinersen Sodium: Icyizere cyo Kudakora neza kw'Imitsi yo mu Mugongo

Uburyo bwo kuvura kanseri y'igifu bwa CAR-T

Uburyo bwo kuvura indwara ya CAR-T ku ndwara ya Neuroblastoma yasubitse/yasubitse

CAR-T yo kuvura indwara ya Systemic Lupus Erythematosus (SLE)

Indwara ya Sickle Cell na Thalassemia

Ubuvuzi bushya bwa Gene butanga icyizere gishya ku barwayi ba Sickle Cell na Thalassemia

FUCASO: Ubuvuzi bwa BCMA CAR-T bugezweho bufite imikorere n'umutekano bidasanzwe

Gukoresha uturemangingo twa NK: Guteza imbere ubuvuzi bwa kanseri birenze imipaka

0102030405

Incamake yuzuye y'ubuvuzi buteye ubwoba bwa kanseri y'amaraso

Ubuvuzi bwa CAR-T, mu magambo ahinnye asobanura Chimeric Antigen Receptor T-Cell Immunotherapy, ni uburyo bugezweho bwo kuvura imiterere y’uturemangingo bukoresha uburyo bwo guhindura uturemangingo twa T tw’umurwayi kugira ngo twibasire kandi tumene uturemangingo twa kanseri. Bitandukanye n’imiti gakondo, ubuvuzi bwa CAR-T bugenewe buri murwayi kandi busaba gukusanya uturemangingo twa T mu maraso y’umurwayi mbere yo kongera kutwongerera mu mubiri nyuma yo gukora inyigo y’imiterere y’uturemangingo.

Twandikire

Ibimenyetso bya CAR-T

● Leukemia y'urukozasoni iteye ubwoba ya B-cell

●Myeloma nyinshi

●Leukemia y'uruhererekane rw'amaraso mu maraso idakira

●Lymphoma itari iya Hodgkin

●Kukwirakwiza lymphoma nini ya B-cell

●SLE (Systemic Lupus Erythematosus)

●Myasthenia gravis

●Izindi ndwara ziterwa n'ubwiyongere bw'umubiri

Imikorere myiza cyane mu buvuzi bwa CAR-T

Ibimenyetso bya CD19+20CAR-T: Abarwayi bafite lymphoma ya B-cell non Hodgkin

Igipimo cya CR cy'ukwezi kumwe	Igipimo cy'ukwezi kumwe cya PR	Igipimo cya OR cy'ukwezi kumwe	CRS≥3	CRES≥3
71.95% (59/82)	25.6 (21/82)	97.55 (80/82)	12.19% (10/82)	0

Ibimenyetso bya CD19+22CAR-T: Kuvura abarwayi ba kanseri y'amaraso ya B-lymphocytic basubiye inyuma kandi badafite CD19

Igipimo cya CR cy'ukwezi kumwe	Igipimo cy'ukwezi kumwe cya PR	Igipimo cya OR cy'ukwezi kumwe	CRS≥3	CRES≥3
92.1% (35/38)	7.9% (3/38)	100% (38/38)	15.79% (6/38)	0

Ibimenyetso bya BCMACAR-T: Kuvura myeloma nyinshi yasubiwemo kandi idashobora kuvura

Igipimo cya CR cy'ukwezi kumwe	Igipimo cy'ukwezi kumwe cya PR	Igipimo cya OR cy'ukwezi kumwe	CRS≥3	CRES≥3
72.41% (21/29)	27.59% (8/29)	100% (29/29)	6.9% (2/29)	0

Ibyiza byacu

● Uburyo bwo kuvura bwite: Buri buvuzi bwa CAR-T bugenewe umurwayi, butuma ahabwa ibisubizo byihariye kandi binoze.

● Amahitamo atandukanye yo kwibandaho: Hamwe n’ubwoko bwinshi bwa antigens zigamije, harimo CD7, CD19, CD20, CD22, na BCMA, ibicuruzwa byacu bya CAR-T bitanga uburyo butandukanye bwo kuvura kanseri zitandukanye z’amaraso n’indwara ziterwa n’ubwiyongere bw’umubiri.

● Intsinzi y'ubuvuzi yagaragaye ko yagaragaye: Uburyo bwacu bwo kuvura bwa CAR-T bwagaragaje imikorere idasanzwe mu ndwara nyinshi zo kwa muganga, hamwe n'uburyo bwo koroherwa no kugabanuka kw'indwara ndetse n'umutekano, bishimangira umwanya wacu nk'umuyobozi mu kuvura indwara ziterwa n'ubudahangarwa bw'umubiri.

● Ihendutse kandi ikoresha amafaranga menshi: Dutanga uburyo bwo guhangana hamwe n’uburyo bwo kuvura bufite ireme ryinshi ku giciro cyoroshye ugereranije n’ibindi bicuruzwa bya CAR-T biri ku isoko.

● Ikoranabuhanga Rigezweho: Dukoresheje iterambere rigezweho mu buhanga mu by’uturemangingo, uburyo bwacu bwo kuvura bwa CAR-T bugaragaza ahazaza ho kuvura kanseri n’indwara ziterwa n’ubwiyongere bw’umubiri.

● Ubufasha bw'inzobere mu by'ubuvuzi: Itsinda ryacu ry’abaganga n’abashakashatsi b’inararibonye ritanga ubuvuzi bwuzuye uhereye ku nama y’ibanze binyuze mu gutanga ubuvuzi no gukurikirana.

Uturemangingo twa CAR-T ubu tuzwi cyane kubera ubushobozi bwatwo mu kuvura abarwayi batakiriye uburyo gakondo bwo kuvura nka chimiotherapie cyangwa gutera umwongo w'amagufwa. Umuryango w'abaganga ku isi yose wemeza ko uburyo bwa CAR-T bwo kuvura bufite akamaro gakomeye mu guhindura umusaruro w'abarwayi.

Inyigo n'ingero zijyanye n'ubuvuzi bwa CAR-T

1. Ubuvuzi bwa CAR-T ku ndwara ya Lupus Erythematosus yo mu mubiri: Ingufu zitangaje mu rubanza rw'abana

Urugero rw’ingenzi rwakorewe mu bitaro bya Kaminuza ya Erlangen rwerekanye akamaro k’ubuvuzi bwa selile ya CAR-T mu kuvura umukobwa w’imyaka 15 urwaye indwara ya lupus erythematosus (SLE). Nyuma y’uburyo butandukanye bwo kuvura bwananiranye, Uresa yahawe ubu buvuzi bushya muri Kamena 2023. Nyuma y’ibyumweru bitatu nyuma yo kuvurwa, ibimenyetso bye byari byararushijeho kuba byiza, bituma akira neza kandi agasubiza imikorere y’impyiko. Iyi ntsinzi ni yo ya mbere ikoreshwa rya CAR-T mu kuvura indwara z’ubudahangarwa bw’umubiri ku bana, igaragaza ubushobozi bwayo bwo kugabanya igihe kirekire no guhindura umusaruro w’abarwayi. Ubundi bushakashatsi burimo gukorwa kugira ngo harebwe uburyo ikoreshwa mu bihe nk’ibyo.

https://www.bioocus.com/news/breakthrough-in-pediatric-autoimmune-disease-car-t-cell-therapy-cures-lupus-patient/

2. Ubuvuzi bwa CAR-T kuri Myeloma nyinshi: Habayeho kwisubiraho gukomeye

Bjørn Simensen, umurwayi w'imyaka 67 ukomoka muri Noruveje, yagize impinduka ikomeye mu rugamba rwe rwo kurwanya indwara ya myeloma nyinshi (IgG lambda, ISS-II) nyuma yo guhabwa ubuvuzi bwa selile za CAR-T. Yabanje kuvurwa mu 2017, ahabwa imiti myinshi ya chimiotherapie, ariko yongera kugaruka mu 2021. Nyuma yo kuvurwa nabi, yoherejwe mu bitaro bya Lu Daopei muri Gashyantare 2022, aho yatoranijwe kuvurwa na CAR-T. Nyuma yo kuvurwa mbere y’uko avurwa, selile ze za CAR-T zari zarashyizwemo. Ku munsi wa 28, ibizamini byakurikiyeho byagaragaje ko nta selile zidasanzwe zo mu maraso mu musemburo we, bigaragaza ko yagize icyo ageraho mu buvuzi bwe.

https://www.bioocus.com/bj-rn-simensen-multiple-myeloma-igg-lambda-iss-ii-product/

3. Uburyo bwo kuvura CD7 CAR-T kuri T-ALL na LBL byasubiwemo: Ingufu n'ingaruka bitanga icyizere

Ubushakashatsi buherutse bwerekana akamaro k'ubuvuzi bwa CD7 chimeric antigen receptor T-cell (CAR-T) hamwe n'uburyo bwa kabiri bwo guteranya uturemangingo tw'amaraso mu maraso (HSCT) ku barwayi ba T-cell acute lymphoblastic leukemia (T-ALL) na lymphoblastic lymphoma (LBL) byasubiwemo. Ubu bushakashatsi bwakorewe mu bitaro bya Hebei Yanda Lu Daopei, bwakorewe ku barwayi 16 babashije kugabanya burundu indwara ya MRD (MRD) nyuma yo kuvurwa. Hamwe n'igipimo cya 75% cy'uko ibisebe byo hanze y'umugongo bigabanuka ndetse n'igipimo cy'umwaka umwe cyo kubaho no kubaho nta kanseri y'amaraso kigabanukaho 58.5% na 51.4%, ubu buryo bushya butanga icyizere cyo kongera kugabanya burundu indwara muri izi kanseri zikomeye.

https://www.bioocus.com/news/promising-outcomes-of-cd7-car-t-therapy-combined-with-second-transplant-in-relapsed-t-all-lbl-patien/

4. Ubuvuzi bwa CAR-T ku ndwara ya B-cell acute lymphoblastic leukemia: Ingufu zitari zisanzweho

Ubushakashatsi buherutse gukorwa bwerekana akamaro kadasanzwe k’ubuvuzi bwa chimeric antigen-T cell (CAR-T) mu kuvura B-cell acute lymphoblastic leukemia (B-ALL). Bwakozwe ku bufatanye na BIOOCUS na Lu Daopei Hospital, bwagaragaje ko umubare munini w’abarwayi bakize burundu, bushyira ubuvuzi bwa CAR-T nk'uburyo bwiza bwo kuvura iyi kanseri y’urumogi. Ibisubizo bishimishije bigaragaza ubushobozi bwo guhindura ubuvuzi bwa CAR-T mu ndwara za kanseri, bitanga icyizere ku barwayi n’imiryango ihura na B-ALL. Uko ubushakashatsi bugenda butera imbere, ubuvuzi bwa CAR-T bugiye kugira uruhare runini mu gihe kizaza cyo kuvura kanseri.

https://www.bioocus.com/news/pioneering-car-t-therapy-in-b-cell-acute-lymphoblastic-leukemia-shows-unprecedented-efficacy/

Uburyo bwo kuvura CAR-T

1. Ikusanyirizo rya T-Cell:

Mu ntangiriro, abaganga bakusanya uturemangingo twa T mu maraso y'umurwayi bakoresheje uburyo bwitwa leukapheresis. Ubusanzwe iki gikorwa kimara amasaha agera kuri 4, aho icyuma gitandukanya amaraso gitandukanya uturemangingo tw'amaraso twera dukenewe hanyuma kigasubiza ibice bisigaye mu mubiri w'umurwayi.

2. Guhindura no Kwagura Genetike:

Uturemangingo twa T twakusanyijwe twoherezwa muri laboratwari kugira ngo duhindurwe mu buryo bw’uturemangingo. Muri iyi ntambwe, uturemangingo twa T tuba twakozwe kugira ngo twibasire kandi dusenye uturemangingo twa kanseri. Iki gikorwa kimara ibyumweru 2-3. Muri iki gihe, uturemangingo twa T tuba twatangiye gukora no kwaguka muri laboratwari kugira ngo tumenye neza ko dushobora kurwanya kanseri.

3. Gutera uturemangingo:

Iyo uturemangingo twa T twakozwe mu buryo bwa “designed T cells” tumaze kwitegura, twongera gushyirwa mu mubiri w'umurwayi binyuze mu guterwa mu mitsi. Iyi ntambwe ituma uturemangingo tw’ubudahangarwa bw’umubiri twahinduwe dushobora kumenya no gukuraho uturemangingo twa kanseri neza.

Abarwayi bashobora kugira ingaruka mbi mu gihe cyo kuvurwa, izikunze kugaragara cyane ni indwara ya cytokine release syndrome (CRS), iterwa n’ubwirinzi bw’umubiri mu gihe cy’isenyuka ry’uturemangingo twa kanseri. Nubwo CRS ishobora kuba ikomeye, iterambere mu buvuzi ryagabanyije cyane ibyago byayo.

Inzira yose yo kuvurwa, kuva ku gukusanya uturemangingo kugeza ku guterwa, akenshi imara ibyumweru 4-6, nubwo igihe nyacyo giterwa n'uko umurwayi amerewe.

Ubufasha bwuzuye ku barwayi mpuzamahanga bajya muri BIOOCUS kuvurwa na CAR-T

Muri BIOOCUS, twiyemeje gutanga ubuvuzi budasanzwe no gushyigikira abarwayi mpuzamahanga bashaka ubuvuzi bwa CAR-T. Serivisi zacu zirambuye zikubiyemo intambwe zose z'urugendo, kuva ku gutegura mbere y'urugendo kugeza ku buvuzi nyuma yo kuvurwa.

1. Kwitegura mbere yo kugenda

Mbere yo kujya muri BIOOCUS, abarwayi bazakorerwa isuzuma ryimbitse mbere yo kugezwa mu bitaro byabo. Ibi birimo gusuzuma neza amateka y’ubuzima, ibizamini by’umubiri, n’ibizamini bireba nko gusuzuma amaraso, inyigo zijyanye n’ishusho, no gusuzuma ubwoko bwa kanseri ivurwa (nka kanseri y’amaraso, kanseri y’amaraso, cyangwa izindi kanseri z’amaraso). Tureba neza ko inyandiko zose z’ubuvuzi, harimo n’ubuvuzi bwabanje, ibisubizo by’ibizamini, n’ibyemeza by’indwara, byoherejwe ku itsinda ryacu kugira ngo ribisuzume kandi ritegure.

2. Ingendo n'Ivuriro

Dufasha mu ngendo zose, harimo gutegura amacumbi no gufatira abarwayi mu bitaro muri BIOOCUS International Medical Center. Iyo abarwayi bagezeyo, bayoborwa mu nzira yo kwakira abarwayi, bigatuma babasha kwinjira mu bitaro mu buryo bworoshye.

3. Uburyo bwo kuvura

Nyuma yo kwakirwa, abarwayi bazakora ibizamini by’ibanze, harimo n’ibizamini kugira ngo bemeze ko bemerewe kuvurwa na CAR-T. Ibi bizasaba gusuzuma uko umurwayi ahagaze kanseri n’ubuzima bwe muri rusange, ndetse no gukusanya amaraso kugira ngo akoreshwe mu gukuramo T-cells. Hanyuma T-cells zakusanyijwe zoherezwa muri laboratwari yacu yemewe na GMP kugira ngo zihindurwe. Iki gikorwa gishobora gufata ibyumweru 2-3.

4. Gutera uturemangingo n'ubuvuzi nyuma yo kuvurwa

Iyo uturemangingo twa CAR-T twahinduwe tumaze kuba twiteguye, abarwayi bazagaruka mu bitaro byacu kugira ngo bahabwe uburyo bwo kubatera. Ubu ni uburyo bwo kuvura rimwe gusa aho uturemangingo twa T twakozwe mu buryo bw’ikoranabuhanga duhabwa mu mitsi. Nyuma yo kubatera, abarwayi bazakomeza gukurikiranwa hafi mu gihe cy’iminsi myinshi kugira ngo barebe ingaruka mbi, nka cytokine release syndrome, ishobora kuba igisubizo cy’ubuvuzi. Itsinda ryacu ry’abaganga ritanga ubufasha n’igenzura rihoraho muri iki gihe gikomeye.

Nyuma yo kuva mu bitaro, BIOOCUS ihuza gahunda yo gukurikirana buri gihe, harimo no gupima muri laboratwari no gusuzuma amashusho, kugira ngo irebe niba ubuvuzi bufite akamaro kandi ikurikirane gukira kw'umurwayi. Abarwayi bazakurikiranirwa hafi niba nta ngaruka zavuye mu buvuzi zatinze, kandi itsinda ryacu rizakomeza kuvugana kugira ngo ritange ubuyobozi n'ubufasha buhoraho.

Muri BIOOCUS, dushyira imbere ubuzima, umutekano, n'ihumure ry'abarwayi bacu mpuzamahanga. Intego yacu ni ugutanga ubuvuzi bwuzuye no kwemeza ko habaho ubufasha kandi bunoze mu rugendo rwo kuvurwa na CAR-T.

Kugira ngo ubone amakuru arambuye ku bijyanye na serivisi zacu n'uburyo twagufasha mu kuvura, twandikire utaziguye.

ibisobanuro2

Submit An Free Inquiry

Our medical team will make an evaluation for you, based on the information you provided. This procedure is free of charge.